Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BROVANA vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
15 mcg (2 m L) by nebulization twice daily, not to exceed 30 mcg/day.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life: approximately 26 hours (range 22–30 hours) in healthy adults; prolonged in hepatic impairment (up to 50% increase).
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily metabolized via glucuronidation (UGT1A1, UGT1A3, UGT1A9) and to a lesser extent by O-demethylation via CYP2D6 and CYP2E1.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Primarily renal (60% unchanged drug); remainder via biliary/fecal (approximately 20%) and metabolic transformation.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
Approximately 75% bound primarily to albumin and alpha-1-acid glycoprotein.
55–65% bound to plasma proteins, primarily albumin.
Approximately 1.9 L/kg (indicating extensive extravascular distribution).
0.4–0.6 L/kg, indicating distribution into total body water.
Inhalation: approximately 9–15% (due to lung deposition and local metabolism; oral bioavailability <2% due to first-pass effect).
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No adjustment required for GFR ≥30 m L/min; insufficient data for GFR <30 m L/min; use with caution.
No dose adjustment required for renal impairment.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Not approved for pediatric use; safety and efficacy not established for patients <18 years.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
No specific dose adjustment; monitor for adverse effects; start at low end of dosing range if renal or hepatic impairment present.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
LABAs increase the risk of asthma-related death. BROVANA is not indicated for the treatment of asthma.
No FDA black box warning exists for this drug.
Paradoxical bronchospasm, cardiovascular effects (tachycardia, hypertension, QT prolongation), hypokalemia, hyperglycemia, immediate hypersensitivity reactions, and use with other beta-agonists.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to arformoterol or any component of the product, or to racemic formoterol.
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
No specific food interactions. Avoid caffeine or other stimulants as they may increase sympathetic side effects (e.g., tremor, tachycardia).
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, arformoterol (the active enantiomer of formoterol) caused fetal malformations (including omphalocele and skeletal abnormalities) at doses approximately 2.4 times the maximum recommended human daily inhalation dose (MRHDID) in rats, and delayed ossification at doses approximately 0.24 times MRHDID in rabbits. Use only if potential benefit justifies potential risk to fetus. First trimester: limited human data; second and third trimesters: may cause preterm labor due to beta-adrenergic receptor stimulation; monitor for uterine contractions.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
No human data on presence in breast milk, effects on breastfed infant, or milk production. Arformoterol is excreted in rat milk at concentrations similar to maternal plasma. Caution advised; consider developmental and health benefits of breastfeeding alongside mother's clinical need for BROVANA. M/P ratio not available.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
No specific dose adjustments established. Pharmacokinetic changes in pregnancy may include increased clearance (e.g., due to increased renal blood flow and metabolic enzyme induction), but no data for arformoterol. Use lowest effective dose; monitor for efficacy and adverse effects. Dose adjustments should be individualized.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Arformoterol (BROVANA) is a long-acting beta-2 agonist (LABA) indicated for maintenance treatment of COPD, not for acute exacerbations. It should not be used with other LABAs. Monitor for paradoxical bronchospasm and cardiovascular effects. Twice-daily dosing, not once-daily like some LABAs.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Use BROVANA exactly as prescribed, twice daily (morning and evening), not for sudden breathing problems.,Do not use more than the prescribed dose; overuse can increase risk of side effects.,Rinse mouth with water after each dose to reduce risk of thrush (if using via nebulizer with a mouthpiece).,Contact your healthcare provider if symptoms worsen or you need your rescue inhaler more often.,Common side effects include headache, chest pain, back pain, diarrhea, and sinusitis.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BROVANA vs AEROLATE SR, answered by our medical review team.
BROVANA is a Bronchodilator that works by BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BROVANA and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BROVANA is: 15 mcg (2 m L) by nebulization twice daily, not to exceed 30 mcg/day.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BROVANA and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BROVANA is classified as Category C. Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, arformoterol (the active enantiomer of formoterol) caused fetal malformations (inclu. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.